What is B. Riley’s Estimate for VNDA FY2025 Earnings?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Investment analysts at B. Riley issued their FY2025 earnings per share (EPS) estimates for Vanda Pharmaceuticals in a report released on Tuesday, November 4th. B. Riley analyst M. El-Saadi anticipates that the biopharmaceutical company will earn ($2.08) per share for the year. B. Riley currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($1.12) per share. B. Riley also issued estimates for Vanda Pharmaceuticals’ Q4 2025 earnings at ($0.74) EPS, FY2026 earnings at ($1.63) EPS, FY2027 earnings at ($0.69) EPS, FY2028 earnings at $0.92 EPS and FY2029 earnings at $1.59 EPS.

Several other brokerages have also recently commented on VNDA. Weiss Ratings restated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Vanda Pharmaceuticals in a research note on Thursday, August 21st. Cantor Fitzgerald reduced their price objective on shares of Vanda Pharmaceuticals from $13.00 to $11.00 and set an “overweight” rating for the company in a research note on Thursday, October 30th. Finally, Wall Street Zen upgraded Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 1st. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Vanda Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $14.00.

Vanda Pharmaceuticals Stock Down 0.7%

Shares of VNDA opened at $4.41 on Friday. Vanda Pharmaceuticals has a twelve month low of $3.81 and a twelve month high of $5.70. The stock has a market capitalization of $260.62 million, a P/E ratio of -3.11 and a beta of 0.78. The company has a 50 day moving average of $4.92 and a 200-day moving average of $4.65.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, October 29th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.07). The firm had revenue of $56.26 million during the quarter, compared to analyst estimates of $58.73 million. Vanda Pharmaceuticals had a negative net margin of 39.70% and a negative return on equity of 16.44%. Vanda Pharmaceuticals has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of VNDA. CWM LLC increased its stake in shares of Vanda Pharmaceuticals by 424.6% during the 2nd quarter. CWM LLC now owns 9,359 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 7,575 shares during the last quarter. PVG Asset Management Corp acquired a new stake in Vanda Pharmaceuticals in the 1st quarter valued at about $48,000. Linden Thomas Advisory Services LLC acquired a new stake in Vanda Pharmaceuticals in the 1st quarter valued at about $49,000. Nations Financial Group Inc. IA ADV bought a new position in Vanda Pharmaceuticals during the first quarter worth about $67,000. Finally, Cerity Partners LLC acquired a new position in Vanda Pharmaceuticals during the second quarter worth approximately $69,000. Institutional investors own 88.14% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.